P01 Administrative Core

P01 行政核心

• 批准号: 10024957
• 负责人: Cesar Augusto Arias
• 金额: $ 16.95万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10024957
• 关键词: Accountability; Address; Advisory Committees; Agriculture; Antibiotic Resistance; Antibiotics; Antimicrobial Resistance; Benchmarking; Budgets; Clinical; Clinical Data; Clostridium difficile; Collaborations; Combating Antibiotic Resistant Bacteria; Communication; Critical Illness; Data; Decision Making; Development; Diagnostic; Disease Progression; Disputes; Effectiveness; Ensure; Enterobacteriaceae; Extended-spectrum β-lactamase; Genomics; Goals; Government; Home environment; Human Resources; Immunocompromised Host; Industrialization; Infection; Intensive Care Units; Leadership; Life; Liquid substance; Logistics; Mediating; Medical; Medical center; Minor; Modern Medicine; Monitor; Online Systems; Operations Research; Organism; Pathogenicity; Patients; Persons; Phenotype; Positioning Attribute; Process; Productivity; Program Reviews; Progress Reports; Proteomics; Public Health; Quality Control; Regimen; Research; Research Activity; Research Personnel; Research Project Grants; Resolution; Sampling; System; Techniques; Texas; Therapeutic; Translating; United Nations; United States National Institutes of Health; Vancomycin resistant enterococcus; Work; carbapenemase; clinical practice; commensal microbes; conflict resolution; data management; data sharing; functional genomics; gastrointestinal; gut colonization; gut microbiota; high risk; improved outcome; insight; meetings; metabolomics; microbiota; microorganism; mortality; multi-drug resistant pathogen; novel; outcome prediction; pathogen; programs; sample collection; success; synergism; treatment strategy

ABSTRACT (Administrative Core) The clinical introduction of antibiotics in 1930s-40s represented a major medical breakthrough enabling many advances in modern medicine, agriculture and industrial practice. Unfortunately, the rise of antibiotic-resistant microorganisms globally is now considered one of the most challenging public health threats of the 21st century. The call for action against the threat of antibiotic resistance has now reached the highest level of government including the Office of the US President (with the creation of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria) and the initiative for global action by the United Nations, among others. Vancomycin-resistant enterococci (VRE), Enterobacteriaceae carrying extended spectrum β-lactamases and carbapenemases (ESBL-E/CRE), and Clostridiodes difficile are particularly concerning for high-risk patients who are immunocompromised and/or admitted to intensive care units (ICUs). Having the potential to cause life- threatening infections, particularly in those patients who have already been subjected to multiple antibiotic regimens, each of these organisms colonize the intestines, and their presence impacts subsequent colonization by other pathogens further contributing to serious disease progression and even mortality in these high-risk patients. Although these pathogens have been studied in isolation, elucidation of the dynamic interactions between pathogens and commensal gut microbiota and their implication for predicting outcomes and, thus, treatment strategies is more urgent than ever and requires a strategic, coordinated effort. The Texas Medical Center in Houston, Texas is home to several world leaders in antimicrobial resistance research and clinical practice with patient access and tremendous expertise in the cutting-edge genomic and phenotypic techniques who are uniquely positioned to perform concerted and synergistic systems-level studies of the multiple players that must be understood to address this challenge. These experts have recognized this exceptional opportunity and the strength of addressing the critical and unmet challenge through the formation of a multi-institutional collaborative research program Dynamics of Colonization and Infection by Multidrug- Resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE). Crucial for the effectiveness of this multi-institutional research effort, is dedicated centralized administrative oversight and support. The Administrative Core will serve as the central “hub” for program oversight, accountability, communication, and project/process coordination for the three Projects and the Functional Genomics Core. To achieve these goals, the Administrative Core will provide integrative accountability and oversight through the Executive Leadership Team and the Internal and External Advisory Committees, and administrative support for all project leaders, research personnel, key collaborators and advisors, and institutional administrative liaisons.

摘要（管理核心） 20 世纪 30 年代至 40 年代抗生素的临床应用代表了一项重大的医学突破，使许多人受益匪浅。 现代医学、农业和工业实践的进步不幸的是抗生素耐药性的增加。 全球微生物现在被认为是 21 世纪最具挑战性的公共卫生威胁之一。 政府最高层已呼吁采取行动应对抗生素耐药性的威胁 包括美国总统办公室（成立了总统抗疫咨询委员会） 抗生素耐药细菌）和联合国全球行动倡议等。 耐万古霉素肠球菌 (VRE)、携带广谱 β-内酰胺酶的肠杆菌科细菌和 碳青霉烯酶 (ESBL-E/CRE) 和艰难梭菌对高危患者尤其重要 免疫功能低下和/或住进重症监护病房 (ICU) 的人 有可能导致生命危险。 威胁感染，尤其是那些已经接受过多种抗生素治疗的患者 方案中，这些微生物中的每一种都会在肠道中定殖，它们的存在会影响随后的定殖 其他病原体进一步导致这些高危人群的严重疾病进展甚至死亡 尽管这些病原体已被单独研究，但仍需阐明其动态相互作用。 病原体和常见肠道微生物群之间的关系及其对预测结果的影响， 因此，治疗策略比以往任何时候都更加紧迫，需要战略性的、协调一致的努力。 德克萨斯州休斯顿的医疗中心是抗菌素耐药性研究和治疗方面几位世界领先者的所在地。 与患者接触的临床实践以及尖端基因组和表型方面的丰富专业知识 具有独特定位的技术，可以对系统进行协调一致和协同的系统级研究 这些专家已经认识到这一点。 通过组建 多机构合作研究项目“多种药物的定植和感染动态” 免疫功能低下和危重患者中的耐药病原体（DYNAMITE）对于患者至关重要。 这项多机构研究工作的有效性在于专门的集中行政监督和 行政核心将作为项目监督、问责、支持的中心“枢纽”。 三个项目和功能基因组核心的沟通和项目/流程协调。 为了实现这些目标，行政核心将通过 执行领导团队和内部和外部咨询委员会，以及行政支持 所有项目负责人、研究人员、主要合作者和顾问以及机构行政联络人。